INTRODUCTION
Cognitive deficit or cognitive impairment is an inclusive term to describe any characteristic that acts as a barrier to the cognition process. 1 The term may describe deficits in global intellectual performance, such as mental retardation. Learning disorders, dyslexia are some specific types of the cognitive deficits, the other may be drug induced cognitive/memory impairment such as cognitive impairment caused by glucocorticoids, and benzodiazepines. 2 It is an intellectual impairment which begins in childhood due to which child shows significant limitations in their ability to learn and function. It may range from vast intellectual impairment with minimal functioning to mild impairment in specific tasks. The areas which may get affected in cognitive deficit may be attention, decision making, perception, judgment, reasoning, memory, language, general knowledge and many more. In children, the impairment leads to poor orientation in academic tasks, school work will be disorganized, and frequently incomplete and are prone to behavioral disturbances. The cause of Cognitive deficits may be congenital or may be caused by environmental factors such as brain injuries, neurological disorders or mental illness. 3, 4 Buddhimandyata (mental retardation) is a condition explained under certain Balgrahas described in various Ayurvedic classics including Kashyap samhita, 5 
Madhava
Nidana, 6 Susruta samhita, 7 etc. Buddhimandyata (mental retardation) is a disease condition where the manah or psyche and 'Manovahastrotas' get affected. There are three functional categories of Manas, i.e., Satva, Raja and Tama.
RESEARCH ARTICLE
In Balbuddhimandyata tamoguna is found to be profoundly vitiated as compared to Rajah and Satvaguna. It is also believed that there is a significant deficit of Sattva Guna in both qualitative and quantitative form in these children. Due to this reason, the children suffering from Buddhimandya are unable to perform the intellectual functions in comparison to their normal counterpart. Some of the causative factors for Buddhimandyata, mentioned in various Ayurvedic classics includes Dauhridd Avamanana (non-fulfillment of desires of pregnant women), Beejadosa (genetic factor), Apathya Ahara-Vihara (incompatible diet and lifestyle), Vegadharana (suppression of natural urges), Yonidosa (gynecological disorders) and Nastikata (non-belief on God) leads to vitiation of vatadosha thus gives rise to various fetal abnormalities like Kubja, Kuni, Pangu, Jada/Mandabudhi, etc. 8, 9 Coming to the management part, no adequate treatment for Buddhimandyata (cognitive deficit) is available in conventional system of medicine, in present scenario. However, Ayurveda has emphasized the role of medhya rasayanas indifferent psychiatric disorders including Buddhimandyata (mental retardation). In light of above, the present clinical study has been conducted to evaluate the role of Sarasvata Ghrita for its efficacy as well as safety in the children who were presented with mild to moderate cognitive deficit.
OBJECTIVES
To evaluate the efficacy and safety of Sarasvata Ghrita in the management of cognitive deficit.
MATERIALS AND METHODS

Study Design
The study was an interventional, open-label executed at ACAMH and NS, NIMHANS, Bangalore, and a peripheral unit of CCRAS, Ministry of AYUSH. The study was approved by Institutional Ethics Committee and was done in accordance with WHO-Good Clinical Practices Guidelines. The Clinical trial has also been registered in Clinical Trial Registry of India (CTRI/2014/03/006656)
Study Participants
A total of 45 participants were enrolled in the trial, from ACAMH and NS. Patients were screened in accordance with the inclusion and exclusion criteria mentioned in the protocol. All the 45 patients following the screening criteria were recruited in the study after obtaining the written informed consent.
Inclusion Criteria
Children of either sex aged between 8-13 years with IQ 63-80 as per Binet Kamat test (BKT), willing and able to participate for three months (consent was obtained from parents/guardians.
Exclusion Criteria
Children with severe infection and/or clinically significant hepatic, respiratory, renal, cardiac, or hematological disorders were excluded from the study. Also those children with abnormal laboratory values at admission like serum creatinine > 0.2 mg/dl, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) > 3 times of their upper limit; serum bilirubin or alkaline phosphatase > 1.5 times the upper limit were also excluded. Patient's guardian who cannot be relied upon to comply with the test procedures or who were unwilling to give informed consent were also not included for the study. Those children were also removed from the study those were having any intramuscular, intravenous corticosteroids within four weeks prior to study entry. Likewise, children having a history of recent and clinically significant drug abuse, preexisting blood dyscrasias, poorly controlled epilepsy, history of head injury, those to whom BKT cant not be administered were also excluded, in whom another investigational drug was used within three months were also excluded. Children who were unlikely to comply with the protocol, e.g., bone marrow hypoplasia, leucopenia, thrombocytopenia were also not included in the study.
Study Interventions
The study medications included Sarasvata Ghrita 10 in the dose of 6 gms twice a day before food with warm water (ushnodaka) for a period of three months. It was procured from GMP certified Ayurvedic pharmaceutical industries and standardized following the standard laid in Ayurvedic Pharmacopoeia of India.
Study Procedure
On the enrolment day at baseline (Visit 1), the patient's demographic profile, medical history, general physical and systemic examination were recorded. Subsequent visits were planned at an interval of one month, 2nd month, and 3rd month. Patients were assessed and given study medications at each subsequent visit. Details of clinical assessment and study schedule are given in Flow Chart 1. At the study site data of all the patients were recorded in pre-designed case report forms (CRFs) and was also JRAS entered in electronic formats (e-formats) designed in ms-excel with many data validation checks to ensure correct data entry. The e-formats and xerox of the CRFs along with the laboratory investigations reports of the patients were sent by the participating centers to the council's headquarters on weekly basis for the purpose of clinical trial monitoring.
Out of the total 45 patients enrolled in the study, four dropped out during the course of the study. Imputation was applied on those four patients. Hence, data of a total 45 patients was used for statistical analysis (Flow Chart 2).
Outcomes
The primary outcome measure was mean change in IQ (by BKT). The secondary outcome measures were a change in modified child mini-mental scale examination (MMMSE), abnormal behavioral test and parental perception evaluation.
Statistical Analysis
Primary outcome and secondary outcome measures were analyzed as mean change in the response from baseline to 3rd month by using paired t-test. A p-value of < 0.05 was considered significant. Relief was assessed as a percentage change in terms of presence of any symptom at baseline and at 3rd month. All statistical analysis was performed using SPPS version 15.0
RESULTS
Data of 45 patients (26 male and 19 female) was used for statistical analysis. Out of which maximum patients 30 (67.7%) were in the age group of 11-13 years. Table 1 shows the demographic profile of the patients.
Among the total patients 29 (64.4%) patients were of Vata-pittaja Sharirik Prakriti. Socio-economic condition was good (above poverty line) in 22 (48.9%) patients. Maximum number of patients was residing in urban area 31 (68.9%). Physical parameters of the patients recorded at baseline of the patients are shown in Table 2 .
Effect of the study medications was assessed by paired t-test on IQ (by BKT) (Graph 1), MMMSE (Graph 2) and abnormal behavioral test (Graph 3) compared at baseline and at 90th day. Table 3 shows the results of the analysis on those parameters. Parental perception evaluation
Flow Chart 1: Study schedule
Flow Chart 2:
Outflow of the patients in the study was also assessed after the treatment. Table 4 shows the results of the analysis.
Safety profile
The effect of this treatment on various safety parameters such as liver function tests and renal function tests were assessed on a baseline and on 90th day visit. The values were within limits during the entire trial period (Graphs 4 to 6). Table 5 shows the effect of the drugs on the safety parameters Values are expressed as n (%) 
DISCUSSION
Intelligence, memory and adequate social atmosphere are responsible for the proper development of a child. Many children, particularly those with cognitive deficiency Values are expressed as mean (SD), $ compared using paired t-test at baseline and 90th day, *p-value of < 0.05 has been considered as significant Values are expressed as mean (SD), $ compared using paired t-test at baseline and 90th day, *p-value of < 0.05 has been considered as significant and learning problems are poorly oriented to academic tasks. They lack initiative and perseverance. School work is disorganized and frequently incomplete. There is also evidence that children with learning disabilities pay less attention than normal learners and this cannot be attributed to IQ alone. The IQ alone cannot judge the learning potentiality of a child because, to be a good learner, a child must have less fluctuation of attention, increased power of concentration, spontaneity in word recognition and capacity to memories things quickly and correctly. 11 In this study thus along with BKT IQ scale, modified child MMMSE, Abnormal Behavioral Test, Abnormal Behavior Checklist (ABC) and in the last parental perception evaluation were evaluated. Sarasvataghrita mentioned in Bhaishajya Ratnavali, swarbheda adhikar 12 was taken in the study. Sarasvata Ghrita a polyherbal medhya compound drug used in traditional medicine for cognition and memory related problems is blended with the drugs which exerts a variety of pharmacological actions including anti-inflammatory, anti-amyloidogenic, anti-cholinesterase, hypolipidmic and anti-oxidant properties. 13 In this present study, Sarasvata Ghrita was used internally to see the effects on changes of IQ (BKT score), MMSE, ABC and parental perception in the cognitive deficiency children. After a period of 90 days of treatment it was observed that maximum no of children were found to have improved IQ, MMSE, ABC and parental perception. This improvement may be due to breakdown of the pathogenesis of cognitive deficit. Sarasvata Ghrita having mostly Kaphavataghna 14 properties which assumes that these drugs may clear the pathway of Manovaha srotas by which these drugs may help in the improvement of IQ, MMSE and ABC scores. Vata is considered as the controller of the mind. So the pacification of the vitiated Vata also plays an important role in the action of the drugs. Further, the main content of Sarasvata Ghrita is goat's milk, which contains taurine, a type of amino acid which stimulates proliferation and new neuron formation to sustain learning and memory. [15] [16] [17] Sarasvata Ghrita contains drugs which are having Medhya Prabhava. 18 It increases the Satvika properties of Mana which acts as Samprapti Vighatana, i.e., breaking of psychopathology to help in the treatment of cognitive deficit.
CONCLUSION
The present study has shown significant result, it can be concluded that Sarasvata Ghrita taken internally by cognitive deficit children is helpful in improving their IQ, MMSE and ABC scores. It was also found safe as it does not produce any harmful effect. As Sarasvata Ghrita is found effective and safe further studies can also be done where Sarasvata Ghrita can be combined with other Medhya drugs to get even better results.
